Posted by Michael Wonder on 11 Aug 2022
European Commission approves Imbruvica (ibrutinib) fixed duration combination for adult patients with previously untreated chronic lymphocytic leukaemia
9 August 2022 - It is the first all oral, fixed duration, once daily treatment based on a Bruton's tyrosine kinase inhibitor for the first-line treatment of patients with chronic lymphocytic leukaemia.
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that they have obtained marketing authorisation from the European Commission for the expanded use of Imbruvica (ibrutinib) in combination with venetoclax as an oral only, fixed-duration treatment in adults with previously untreated chronic lymphocytic leukaemia.
